151 related articles for article (PubMed ID: 27829175)
1. Pathologic and immunologic characteristics of coxsackievirus A16 infection in rhesus macaques.
Wang J; Zhang Y; Zhang X; Hu Y; Dong C; Liu L; Yang E; Che Y; Pu J; Wang X; Song J; Liao Y; Feng M; Liang Y; Zhao T; Jiang L; He Z; Lu S; Wang L; Li Y; Fan S; Guo L; Li Q
Virology; 2017 Jan; 500():198-208. PubMed ID: 27829175
[TBL] [Abstract][Full Text] [Related]
2. Similar protective immunity induced by an inactivated enterovirus 71 (EV71) vaccine in neonatal rhesus macaques and children.
Zhang Y; Wang L; Liao Y; Liu L; Ma K; Yang E; Wang J; Che Y; Jiang L; Pu J; Guo L; Feng M; Liang Y; Cui W; Yang H; Li Q
Vaccine; 2015 Nov; 33(46):6290-7. PubMed ID: 26419198
[TBL] [Abstract][Full Text] [Related]
3. A Neonatal Murine Model of Coxsackievirus A6 Infection for Evaluation of Antiviral and Vaccine Efficacy.
Zhang Z; Dong Z; Wei Q; Carr MJ; Li J; Ding S; Tong Y; Li D; Shi W
J Virol; 2017 May; 91(9):. PubMed ID: 28250116
[TBL] [Abstract][Full Text] [Related]
4. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease.
Lim H; In HJ; Lee JA; Sik Yoo J; Lee SW; Chung GT; Choi YK; Chung JK; Cho SJ; Lee JW
Vaccine; 2018 Jun; 36(24):3445-3452. PubMed ID: 29739716
[TBL] [Abstract][Full Text] [Related]
5. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.
Liu CC; Guo MS; Wu SR; Lin HY; Yang YT; Liu WC; Chow YH; Shieh DB; Wang JR; Chong P
Antiviral Res; 2016 May; 129():58-66. PubMed ID: 26899790
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
[TBL] [Abstract][Full Text] [Related]
7. Immune responses of a CV-A16 live attenuated candidate strain and its protective effects in rhesus monkeys.
Yang T; Xie T; Li H; Song X; Yue L; Wang X; Shen D; Ma K; Jiang Q; Long R; Yang R; He X; Zhang Y; Xie Z; Li Q
Emerg Microbes Infect; 2020 Dec; 9(1):2136-2146. PubMed ID: 32930072
[TBL] [Abstract][Full Text] [Related]
8. Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo.
Yao X; Mao Q; Li Y; Hao C; Bian L; Chen P; Gao F; Wu X; Lu W; Gao Q; Li X; Liang Z
Hum Vaccin Immunother; 2018 May; 14(5):1275-1282. PubMed ID: 29337652
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice.
Caine EA; Fuchs J; Das SC; Partidos CD; Osorio JE
Viruses; 2015 Nov; 7(11):5919-32. PubMed ID: 26593938
[TBL] [Abstract][Full Text] [Related]
10. VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population.
Tan S; Tan X; Sun X; Lu G; Chen CC; Yan J; Liu J; Xu W; Gao GF
J Immunol; 2013 Aug; 191(4):1637-47. PubMed ID: 23863902
[TBL] [Abstract][Full Text] [Related]
11. Intranasal immunization with coxsackievirus A16 virus-like particles confers protection against lethal infection in neonatal mice.
Chen X; Zhang Y; Mao N; Zhu S; Ji T; Xu W
Arch Virol; 2019 Dec; 164(12):2975-2984. PubMed ID: 31570994
[TBL] [Abstract][Full Text] [Related]
12. Study of integrated protective immunity induced in rhesus macaques by the intradermal administration of a bivalent EV71-CA16 inactivated vaccine.
Fan S; Liao Y; Jiang G; Jiang L; Wang L; Xu X; Feng M; Yang E; Zhang Y; Cui W; Li Q
Vaccine; 2020 Feb; 38(8):2034-2044. PubMed ID: 31982260
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a coxsackievirus A6 vaccine candidate in an actively immunized mouse model.
Qian SS; Wei ZN; Jin WP; Wu J; Zhou YP; Meng SL; Guo J; Wang ZJ; Shen S
Emerg Microbes Infect; 2021 Dec; 10(1):763-773. PubMed ID: 33739899
[TBL] [Abstract][Full Text] [Related]
14. A 10-Day-Old Murine Model of Coxsackievirus A6 Infection for the Evaluation of Vaccines and Antiviral Drugs.
Jiang Z; Zhang Y; Lin H; Cheng Q; Lu X; Liu W; Zhou R; Zhong B; Tian X
Front Immunol; 2021; 12():665197. PubMed ID: 34054834
[TBL] [Abstract][Full Text] [Related]
15. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection.
Cai Y; Liu Q; Huang X; Li D; Ku Z; Zhang Y; Huang Z
Vaccine; 2013 Apr; 31(18):2215-21. PubMed ID: 23499596
[TBL] [Abstract][Full Text] [Related]
16. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.
Mao Q; Wang Y; Shao J; Ying Z; Gao F; Yao X; Li C; Ye Q; Xu M; Li R; Zhu F; Liang Z
Hum Vaccin Immunother; 2015; 11(11):2723-33. PubMed ID: 25715318
[TBL] [Abstract][Full Text] [Related]
17. Advances in Antigenic Peptide-Based Vaccine and Neutralizing Antibodies against Viruses Causing Hand, Foot, and Mouth Disease.
Anasir MI; Poh CL
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871133
[TBL] [Abstract][Full Text] [Related]
18. [Expression of Type-Ι Interferon Production Pathway-Related Genes Induced by Infection Due to Enterovirus 71 or Coxsackievirus A16 in Normal Human Airway Epithelial Cells].
Song J; Hu Y; Li J; Wang J; Guo L; Zheng H; Ning R; Wang L; Li Q; Liu L
Bing Du Xue Bao; 2016 Nov; 32(6):694-701. PubMed ID: 30004199
[TBL] [Abstract][Full Text] [Related]
19. A novel orally infected hamster model for Coxsackievirus A16 hand-foot-and-mouth disease and encephalomyelitis.
Hooi YT; Ong KC; Tan SH; Perera D; Wong KT
Lab Invest; 2020 Sep; 100(9):1262-1275. PubMed ID: 32601355
[TBL] [Abstract][Full Text] [Related]
20. Is a multivalent hand, foot, and mouth disease vaccine feasible?
Klein M; Chong P
Hum Vaccin Immunother; 2015; 11(11):2688-704. PubMed ID: 26009802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
